TITLE

EMERGING THERAPIES IN SEVERE SEPSIS

AUTHOR(S)
Finney, S. J.; Evans, T. W.
PUB. DATE
October 2002
SOURCE
Thorax;Oct2002 Supplement 2, Vol. 57, pii8
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Context Activation of the coagulation system and depletion of endogenous anticoagulants are frequently found in patients with severe sepsis and septic shock. Diffuse microthrombus formation may induce organ dysfunction and lead to excess mortality in septic shock Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients. Objective: To determine if high-dose antithrombin Ill (administered within 6 hours of onset) would provide a survival advantage in patients with severe sepsis and septic shock Design and setting: Double-blind, placebo-controlled, multicenter phase 3 clinical trial in patients with severe sepsis (the kyberSept trial) was conducted from March 1997 through January2000. Patients: A total of 2314 adult patients were randomized into two equal groups of 1157 to receive either intra venous antithrombin III (30 000 lU in total over 4 days) or a placebo (1% human albumin). Main outcome measure: All-cause mortality 28 days after initiation of study medication. Results: Overall mortality at 28 days in the antithrombin Ill treatment group was 38.9% v 38.7% in the placebo group (p=0.94). Secondary end points, including mortality at 56 and 90 days and survival time in the intensive care unit, did not differ between the antithrombin Ill and placebo groups. In the subgroup of patients who did not receive concomitant heparin during the 4 day treatment phase (n=698), the 28-day mortality was nonsignificantly lower in the antithrombin Ill group (37.8%) than in the placebo group (43.6%) (p=0.08). This trend became significant after 90 days (n-686; 44.9% for antithrombin Ill group v 52.5% for placebo group; p=0.03). In patients receiving antithrombin Ill and concomitant heparin, a significantly increased bleeding incidence was observed (23.8% for antithrombin Ill group v 13.5% for placebo group; p<0.00l). Conclusions: High-dose antithrombin Ill therapy had no effect on 28-day all-cause mortality in adult patients with severe sepsis and septic shock when administered within 6 hours after the onset. High-dose antithrombin Ill was associated with an increased risk of hemorrhage when administered with heparin. There was some evidence to suggest a treatment benefit of antithrombin III in the subgroup of patients not receiving concomitant heparin.
ACCESSION #
12915337

 

Related Articles

  • Fisiopatologia de la septicemia: un enfoque molecular. Pablo Membreño Mann, Juan // Medicina Interna de Mexico;jul/ago2008, Vol. 24 Issue 4, p304 

    Sepsis is a main cause for morbidity in intensive therapy units. Its mortality goes from 20 to 50%, according to the associated illness. This condition has not only an infectious origin, but causes several clinical and biochemical manifestations determined by its physiopathology. Inflammation...

  • The Effects of Triiodothyronine Augmentation on Antithrombin III Levels in Sepsis. Chapital, Alyssa D.; Hendrick, Steven R.; Lloyd, Larry; Pieper, David // American Surgeon;Mar2001, Vol. 67 Issue 3, p253 

    Sepsis and multisystem organ failure are often associated with disseminated intravascular coagulation and consumption of coagulation inhibitors such as antithrombin III (ATIII). The “sick euthyroid syndrome” is also seen in association with significant illnesses and consists of...

  • Coagulation inhibitors in sepsis and disseminated intravascular coagulation. Lee, W. L.; Downey, G. P. // Intensive Care Medicine;Nov2000, Vol. 26 Issue 11, p1701 

    Discusses the physiologic inhibitors of coagulation as potential targets for therapeutic intervention in disseminated intravascular coagulation (DIC). Characterization of the syndrome of DIC; Use of antithrombin III in sepsis and DIC; Implication of DIC in the development of multiple organ failure.

  • Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Karnad, Dilip; Bhadade, Rakesh; Verma, Pradeep; Moulick, Nivedita; Daga, Mradul; Chafekar, Neelima; Iyer, Shivakumar // Intensive Care Medicine;Jun2014, Vol. 40 Issue 6, p830 

    Purpose: Ulinastatin, a serine protease inhibitor, inhibits several pro-inflammatory proteases and decreases inflammatory cytokine levels and mortality in experimental sepsis. We studied the effect of ulinastatin on 28-day all-cause mortality in a double-blind trial in patients with severe...

  • Recent Advances in Marine Algal Anticoagulants. Matsubara, Kiminori // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Mar2004, Vol. 2 Issue 1, p13 

    A large number of anticoagulant polysaccharides from marine algae have been isolated and characterized. Algal anticoagulant polysaccharides exert their anticoagulant activity through potentiating antithrombin III (AT III) and / or heparin cofactor II (HC II) that are important endogenous...

  • Patients with APC Resistance Compared with Those with Other Clotting Inhibitor Deficiencies Show Later Onset of Venous Thrombosis During Oral Contraception. Girolami, Antonio; Simioni, Paolo; Zanardi, Sandra; Scarano, Luigi; Girolami, Bruno // Clinical & Applied Thrombosis/Hemostasis;Fall1995, Vol. 1 Issue 4, p274 

    The prevalence of deep vein thrombosis in female patients with antithrombin III (AT III), protein C, or protein S deficiency who are on oral contraception has been compared with that of patients with activated protein C (APC) resistance. In the latter case the prevalence was lower (36.4%) than...

  • ANTITHROMBIN III  // Davis's Comprehensive Handbook of Laboratory & Diagnostic Tests ;Jan2006, p161 

    Anti-thrombin III (AT-III) can inhibit thrombin and factors IX, X, XI, and XII. It is a heparin cofactor, interacting with heparin and thrombin. AT-III acts to increase the rate at which thrombin is neutralized or inhibited, and it decreases the total quantity of thrombin inhibited. Patients...

  • Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory... Bone, Roger C. // Annals of Internal Medicine;10/15/96, Vol. 125 Issue 8, p680 

    Stresses the need to revise the current understanding of sepsis and multiple organ dysfunction. Incompleteness of previous theories for the pathogenesis of sepsis and multiple organ dysfunction; Overlooking of patients who have less severe manifestations of the diseases.

  • Extended prophylaxis with idraparinux prevented recurrence of venous thromboembolism but increased risk for bleeding.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p20 

    The article presents a study which examines the effectiveness of idraparinux in treating patients with venous thromboembolism (VTE) who have completed six months of anticoagulant therapy. In patients with VTE who had completed six months of anticoagulant therapy, study shows that idraparinux...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics